Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Siemens Healthineers stock has delivered a decline of about 30.1% over the past 5 years, yet the current valuation checks still suggest the shares trade on the cheap side rather than pricing in high expectations. For investors, that mix of weak long term returns and a strong value signal raises the question of whether the market is being too cautious on the stock.
The roughly 30.1% share price decline over 5 years points to a stock that has struggled to create positive returns for long term holders.
Growing focus on laboratory services and product launches such as the expanded capillary testing menu can support expectations for future earnings. However, execution risk around turning these initiatives into sustained profit growth may still weigh on how the market values Siemens Healthineers.
The company screens as undervalued on the broader checks, with a high value score of 6 out of 6 suggesting the current price sits below what many metrics would imply.
The issue now is whether that strong value signal offers enough comfort given Siemens Healthineers' track record of weak long term returns.
Siemens Healthineers delivered -18.7% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry.
The P/E ratio suits Siemens Healthineers because earnings are a key focus for investors in established medical equipment companies. The stock currently trades on about 19.6x earnings, which sits below both the medical equipment industry average of roughly 24.9x and the peer group average of about 24.1x. That gap points to a market valuation that is more cautious than the typical company in the sector.
The tailored fair P/E ratio for Siemens Healthineers is estimated at about 25.3x. This is higher than the current 19.6x level, which indicates that the stock trades at a discount to what many would expect given its profile, margins and risk characteristics. Despite the recent focus on expanding laboratory services and new capillary testing products, the current P/E still prices Siemens Healthineers below both its fair multiple and the sector benchmarks.
On the P/E multiple, Siemens Healthineers stock appears undervalued compared with both its fair ratio and medical equipment peers.
See what the numbers say about this price — find out in our valuation breakdown.
Simply Wall St Narratives for Siemens Healthineers pick up from this valuation gap and describe what kind of growth, margins and earnings path would need to occur for the stock to be worth materially more or less than today's price. Each Narrative links a specific set of catalysts and risks to an implied fair value, so you can track over time which version of Siemens Healthineers' story is closest to reality on the Community page.
One of the top community narratives on Siemens Healthineers: 19% undervalued
"Expansion of long-term Value Partnerships with hospitals and healthcare systems is shifting the business mix toward higher recurring revenue streams, which help stabilize earnings…"
Read one of the top narratives on Siemens Healthineers
Do you think there's more to the story for Siemens Healthineers? Head over to our Community to see what others are saying!
For Siemens Healthineers, the key takeaway is that market multiples still point to an undervalued stock rather than one priced for perfection. The valuation gap versus peers only really closes if the company converts its laboratory expansion and product pipeline into steadier earnings and higher quality recurring revenue. The crux for investors is whether that discount reflects genuine caution around execution or an excessive penalty on a business that could deliver more consistent profitability. That judgment on execution risk versus opportunity is what will likely matter most from here.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SHL.DE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]